{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:55:56Z","timestamp":1794059756830,"version":"4.8.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670164"],"award-info":[{"award-number":["81670164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730003"],"award-info":[{"award-number":["81730003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Clinical Research Center for Hematologic Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00928-1","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:02:50Z","timestamp":1696982570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia"],"prefix":"10.1038","volume":"13","author":[{"given":"Keyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4643-2098","authenticated-orcid":false,"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4609-616X","authenticated-orcid":false,"given":"Shengli","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1766-7891","authenticated-orcid":false,"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7560-7195","authenticated-orcid":false,"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aining","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0610-8723","authenticated-orcid":false,"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":false,"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8015-3546","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"928_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"928_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00503-6","volume":"11","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021;11:114.","journal-title":"Blood Cancer J"},{"key":"928_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"928_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502\u201326.","journal-title":"Am J Hematol"},{"key":"928_CR5","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1002\/ajh.26057","volume":"96","author":"S Arslan","year":"2021","unstructured":"Arslan S, Zhang J, Dhakal P, Moran J, Naidoo N, Lombardi J, et al. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. Am J Hematol. 2021;96:E59\u201363.","journal-title":"Am J Hematol"},{"key":"928_CR6","first-page":"134","volume":"43","author":"WJ Yu","year":"2022","unstructured":"Yu WJ, Jia JS, Wang J, Tang FF, Gong LZ, Liu XH, et al. Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience. Zhonghua Xue Ye Xue Za Zhi. 2022;43:134\u201340.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"928_CR7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/ng.3709","volume":"48","author":"ZJ Faber","year":"2016","unstructured":"Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48:1551\u20136.","journal-title":"Nat Genet"},{"key":"928_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","volume":"127","author":"N Duployez","year":"2016","unstructured":"Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127:2451\u20139.","journal-title":"Blood"},{"key":"928_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3892\/or.2013.2459","volume":"30","author":"WY Zhuang","year":"2013","unstructured":"Zhuang WY, Cen JN, Zhao Y, Chen ZX. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line. Oncol Rep. 2013;30:185\u201392.","journal-title":"Oncol Rep"},{"key":"928_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1182\/blood-2012-01-403212","volume":"120","author":"FS Chou","year":"2012","unstructured":"Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, et al. The thrombopoietin\/MPL\/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. Blood. 2012;120:709\u201319.","journal-title":"Blood"},{"key":"928_CR11","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.blre.2022.101036","volume":"59","author":"P Dhakal","year":"2023","unstructured":"Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR. Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold? Blood Rev. 2023;59:101036.","journal-title":"Blood Rev"},{"key":"928_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, et al. Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial. J Hematol Oncol. 2023;16:42.","journal-title":"J Hematol Oncol"},{"key":"928_CR13","doi-asserted-by":"publisher","first-page":"841276","DOI":"10.3389\/fonc.2022.841276","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Wang J, Ge SS, Qiu QC, Du JH, Shan SS, et al. Combination of venetoclax and midostaurin efficiently suppressed relapsed t(8;21)acute myeloid leukemia with mutant KIT after failure of venetoclax plus azacitidine treatment. Front Oncol. 2022;12:841276.","journal-title":"Front Oncol"},{"key":"928_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ajh.26496","volume":"97","author":"J Senapati","year":"2022","unstructured":"Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, et al. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2022;97:574\u201382.","journal-title":"Am J Hematol"},{"key":"928_CR15","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106:894\u20138.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00928-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00928-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00928-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T17:06:24Z","timestamp":1700327184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00928-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00928-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}